PL368409A1 - Pochodne triazolilo-imidazopirydyny i triazolilopuryn użyteczne jako ligandy receptora adenyzowego A2a oraz ich zastosowanie jako leków - Google Patents
Pochodne triazolilo-imidazopirydyny i triazolilopuryn użyteczne jako ligandy receptora adenyzowego A2a oraz ich zastosowanie jako lekówInfo
- Publication number
- PL368409A1 PL368409A1 PL02368409A PL36840902A PL368409A1 PL 368409 A1 PL368409 A1 PL 368409A1 PL 02368409 A PL02368409 A PL 02368409A PL 36840902 A PL36840902 A PL 36840902A PL 368409 A1 PL368409 A1 PL 368409A1
- Authority
- PL
- Poland
- Prior art keywords
- linear
- branched
- alkyl
- aryl
- alkenyl
- Prior art date
Links
- 239000003814 drug Substances 0.000 title abstract 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 title 2
- 239000002126 C01EB10 - Adenosine Substances 0.000 title 1
- 229960005305 adenosine Drugs 0.000 title 1
- 239000003446 ligand Substances 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 5
- 125000005915 C6-C14 aryl group Chemical group 0.000 abstract 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 3
- 125000003342 alkenyl group Chemical group 0.000 abstract 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 2
- 125000003302 alkenyloxy group Chemical group 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- 125000006727 (C1-C6) alkenyl group Chemical group 0.000 abstract 1
- 102000007471 Adenosine A2A receptor Human genes 0.000 abstract 1
- 108010085277 Adenosine A2A receptor Proteins 0.000 abstract 1
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 abstract 1
- 101100294115 Caenorhabditis elegans nhr-4 gene Chemical group 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 abstract 1
- 125000003277 amino group Chemical group 0.000 abstract 1
- 125000006620 amino-(C1-C6) alkyl group Chemical group 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT2001RM000465A ITRM20010465A1 (it) | 2001-07-31 | 2001-07-31 | Derivati della triazolil-imidazopiridina e delle triazolilpurine utili come ligandi del recettore a2a dell'adenosina e loro uso come medicam |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PL368409A1 true PL368409A1 (pl) | 2005-03-21 |
| PL217269B1 PL217269B1 (pl) | 2014-06-30 |
Family
ID=11455703
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL368409A PL217269B1 (pl) | 2001-07-31 | 2002-07-25 | Pochodne triazoliloimidazopirydyny i triazolilopuryny, zawierająca je kompozycja farmaceutyczna, ich zastosowanie, sposób ich otrzymywania oraz związki pośrednie wykorzystywane w tym sposobie |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US7230102B2 (pl) |
| EP (1) | EP1412354B1 (pl) |
| JP (1) | JP4366186B2 (pl) |
| KR (1) | KR100884818B1 (pl) |
| CN (1) | CN1271070C (pl) |
| AT (1) | ATE325796T1 (pl) |
| AU (1) | AU2002326146B2 (pl) |
| BR (1) | BR0211550A (pl) |
| CA (1) | CA2451279C (pl) |
| DE (1) | DE60211343T2 (pl) |
| DK (1) | DK1412354T3 (pl) |
| ES (1) | ES2263810T3 (pl) |
| HU (1) | HU228985B1 (pl) |
| IT (1) | ITRM20010465A1 (pl) |
| MX (1) | MXPA04000886A (pl) |
| PL (1) | PL217269B1 (pl) |
| PT (1) | PT1412354E (pl) |
| WO (1) | WO2003011864A1 (pl) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4335000B2 (ja) * | 2001-06-29 | 2009-09-30 | シーブイ・セラピューティクス・インコーポレイテッド | Ａ２ｂアデノシン・レセプタ拮抗剤 |
| ITRM20010465A1 (it) * | 2001-07-31 | 2003-01-31 | Sigma Tau Ind Farmaceuti | Derivati della triazolil-imidazopiridina e delle triazolilpurine utili come ligandi del recettore a2a dell'adenosina e loro uso come medicam |
| ES2279903T3 (es) * | 2001-12-18 | 2007-09-01 | Cv Therapeutics, Inc. | Antagonistas del receptor a2a de adenosina. |
| US8012964B2 (en) | 2004-03-26 | 2011-09-06 | Dainippon Sumitomo Pharma Co., Ltd. | 9-substituted 8-oxoadenine compound |
| EP2007765B1 (en) * | 2006-03-23 | 2012-06-27 | Novartis AG | Immunopotentiating compounds |
| WO2008004948A1 (en) | 2006-07-05 | 2008-01-10 | Astrazeneca Ab | 8-oxoadenine derivatives acting as modulators of tlr7 |
| TW200831105A (en) | 2006-12-14 | 2008-08-01 | Astrazeneca Ab | Novel compounds |
| SI2132209T1 (sl) | 2007-03-19 | 2014-05-30 | Astrazeneca Ab | Spojine 9-substituiranega-8-okso-adenina, kot modulatorji Toll-like receptorja (TLR7) |
| JP5329444B2 (ja) | 2007-03-19 | 2013-10-30 | アストラゼネカ・アクチエボラーグ | Ｔｏｌｌ様受容体（ｔｌｒ７）モジュレーターとしての９−置換−８−オキソ−アデニン化合物 |
| BRPI0808301B1 (pt) * | 2007-03-20 | 2022-05-03 | Curis, Inc | Composto e composição farmacêutica |
| AR065784A1 (es) * | 2007-03-20 | 2009-07-01 | Dainippon Sumitomo Pharma Co | Derivados de 8-oxo adenina,medicamentos que los contienen y usos como agentes terapeuticos para enfermedades alergicas, antivirales o antibacterianas. |
| EP2138497A4 (en) | 2007-03-20 | 2012-01-04 | Dainippon Sumitomo Pharma Co | NEW ADENINE CONNECTION |
| EP2155743B1 (en) * | 2007-05-08 | 2012-08-29 | AstraZeneca AB | Imidazoquinolines with immuno-modulating properties |
| PE20091156A1 (es) | 2007-12-17 | 2009-09-03 | Astrazeneca Ab | Sales de (3-{[[3-(6-amino-2-butoxi-8-oxo-7,8-dihidro-9h-purin-9-il)propil](3-morfolin-4-ilpropil)amino]metil}fenil)acetato de metilo |
| JPWO2009091031A1 (ja) * | 2008-01-17 | 2011-05-26 | 大日本住友製薬株式会社 | アデニン化合物の製造方法 |
| WO2009091032A1 (ja) | 2008-01-17 | 2009-07-23 | Dainippon Sumitomo Pharma Co., Ltd. | アデニン化合物の製造方法 |
| TWI473614B (zh) * | 2008-05-29 | 2015-02-21 | Kyowa Hakko Kirin Co Ltd | Anti-analgesic inhibitors |
| KR20110036602A (ko) | 2008-07-03 | 2011-04-07 | 서트리스 파마슈티컬즈, 인코포레이티드 | 시르투인 조절제로서의 벤즈이미다졸 및 관련 유사체 |
| JP5599311B2 (ja) * | 2008-07-23 | 2014-10-01 | 協和発酵キリン株式会社 | 片頭痛治療剤 |
| HUE025704T2 (en) | 2009-03-20 | 2016-04-28 | Sigma Tau Ind Farmaceuti | Oxidized triazolyl purine derivatives used as adenosine A2A receptor ligands and their use as medicaments |
| CN106377540B (zh) | 2009-11-13 | 2019-08-16 | 中央研究院 | 预防及治疗神经退化疾病的双功能化合物 |
| EP2507237A1 (en) * | 2009-12-03 | 2012-10-10 | Dainippon Sumitomo Pharma Co., Ltd. | Imidazoquinolines which act via toll - like receptors (tlr) |
| EP2657236A4 (en) * | 2010-11-24 | 2014-02-26 | Yamasa Corp | NEW 2-ALKYNYL-N9-PROPARGYLADENINE AND ITS MEDICAL USE |
| WO2012080728A1 (en) | 2010-12-16 | 2012-06-21 | Astrazeneca Ab | Imidazo [4, 5 -c] quinolin- 1 -yl derivative useful in therapy |
| ES2627433T3 (es) | 2010-12-17 | 2017-07-28 | Sumitomo Dainippon Pharma Co., Ltd. | Derivados de purina |
| CA2902833A1 (en) | 2013-03-15 | 2014-09-18 | Syngenta Participations Ag | Microbicidally active imidazopyridine derivatives |
| CN105622495A (zh) * | 2016-03-23 | 2016-06-01 | 叶芳 | 4-氯-3-硝基吡啶及其制备方法 |
| PL3280414T3 (pl) | 2016-04-15 | 2024-06-24 | Oxford University Innovation Limited | Modulatory receptora adenozyny w leczeniu schorzeń rytmu okołodobowego |
| WO2025080645A1 (en) * | 2023-10-10 | 2025-04-17 | Regranion, Llc | Methods and compositions for treating bullous pemphigoid |
| GB202319534D0 (en) * | 2023-12-19 | 2024-01-31 | Circadian Therapeutics Ltd | Dosage regimen |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1990009178A1 (en) | 1989-01-31 | 1990-08-23 | Whitby Research, Inc. | N6-substituted 9-methyladenines: a new class of adenosine receptor antagonists |
| US5670501A (en) * | 1994-09-01 | 1997-09-23 | Discovery Therapeutics, Inc. | N-substituted 9-alkyladenines |
| CA2315736A1 (en) * | 1998-01-05 | 1999-07-15 | Eisai Co., Ltd. | Purine compounds and adenosine a2 receptor antagonist as preventive or therapeutic for diabetes mellitus |
| GB9915437D0 (en) * | 1999-07-01 | 1999-09-01 | Cerebrus Ltd | Chemical compounds III |
| JP4335000B2 (ja) * | 2001-06-29 | 2009-09-30 | シーブイ・セラピューティクス・インコーポレイテッド | Ａ２ｂアデノシン・レセプタ拮抗剤 |
| ITRM20010465A1 (it) * | 2001-07-31 | 2003-01-31 | Sigma Tau Ind Farmaceuti | Derivati della triazolil-imidazopiridina e delle triazolilpurine utili come ligandi del recettore a2a dell'adenosina e loro uso come medicam |
-
2001
- 2001-07-31 IT IT2001RM000465A patent/ITRM20010465A1/it unknown
-
2002
- 2002-07-25 DK DK02760555T patent/DK1412354T3/da active
- 2002-07-25 US US10/484,491 patent/US7230102B2/en not_active Expired - Fee Related
- 2002-07-25 AT AT02760555T patent/ATE325796T1/de active
- 2002-07-25 KR KR1020047000173A patent/KR100884818B1/ko not_active Expired - Fee Related
- 2002-07-25 DE DE60211343T patent/DE60211343T2/de not_active Expired - Lifetime
- 2002-07-25 PT PT02760555T patent/PT1412354E/pt unknown
- 2002-07-25 JP JP2003517056A patent/JP4366186B2/ja not_active Expired - Fee Related
- 2002-07-25 AU AU2002326146A patent/AU2002326146B2/en not_active Ceased
- 2002-07-25 EP EP02760555A patent/EP1412354B1/en not_active Expired - Lifetime
- 2002-07-25 WO PCT/IT2002/000489 patent/WO2003011864A1/en not_active Ceased
- 2002-07-25 HU HU0401987A patent/HU228985B1/hu not_active IP Right Cessation
- 2002-07-25 CN CNB028138481A patent/CN1271070C/zh not_active Expired - Fee Related
- 2002-07-25 MX MXPA04000886A patent/MXPA04000886A/es active IP Right Grant
- 2002-07-25 CA CA2451279A patent/CA2451279C/en not_active Expired - Fee Related
- 2002-07-25 PL PL368409A patent/PL217269B1/pl unknown
- 2002-07-25 BR BR0211550-6A patent/BR0211550A/pt not_active IP Right Cessation
- 2002-07-25 ES ES02760555T patent/ES2263810T3/es not_active Expired - Lifetime
-
2007
- 2007-05-04 US US11/797,566 patent/US7528252B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| KR20040023641A (ko) | 2004-03-18 |
| US20040204428A1 (en) | 2004-10-14 |
| CN1525974A (zh) | 2004-09-01 |
| JP4366186B2 (ja) | 2009-11-18 |
| ITRM20010465A0 (it) | 2001-07-31 |
| DK1412354T3 (da) | 2006-09-18 |
| US20070249638A1 (en) | 2007-10-25 |
| HK1068334A1 (en) | 2005-04-29 |
| KR100884818B1 (ko) | 2009-02-20 |
| CA2451279A1 (en) | 2003-02-13 |
| DE60211343T2 (de) | 2007-05-10 |
| PT1412354E (pt) | 2006-09-29 |
| US7230102B2 (en) | 2007-06-12 |
| CA2451279C (en) | 2011-05-10 |
| EP1412354B1 (en) | 2006-05-10 |
| DE60211343D1 (de) | 2006-06-14 |
| WO2003011864A1 (en) | 2003-02-13 |
| BR0211550A (pt) | 2004-07-13 |
| CN1271070C (zh) | 2006-08-23 |
| PL217269B1 (pl) | 2014-06-30 |
| EP1412354A1 (en) | 2004-04-28 |
| ATE325796T1 (de) | 2006-06-15 |
| HU228985B1 (en) | 2013-07-29 |
| AU2002326146B2 (en) | 2008-05-01 |
| ES2263810T3 (es) | 2006-12-16 |
| JP2005500355A (ja) | 2005-01-06 |
| HUP0401987A3 (en) | 2012-12-28 |
| US7528252B2 (en) | 2009-05-05 |
| ITRM20010465A1 (it) | 2003-01-31 |
| HUP0401987A2 (hu) | 2005-01-28 |
| MXPA04000886A (es) | 2004-06-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE325796T1 (de) | Derivate von triazolyl-imidazopyridine und von triazolylpurine als ligande des adenosine a2a rezeptoren und ihre verwendung als medicamente | |
| TW200716528A (en) | Cyclopropanecarboxamide derivatives | |
| HUP0401047A2 (hu) | Triazolo[4,5-d]pirimidin-származékok, alkalmazásuk purinergikus receptor-antagonistákként és a vegyületet tartalmazó gyógyszerkészítmények | |
| MY139357A (en) | Novel benzoimidazole derivatives useful as antiproliferative agents | |
| UY25679A1 (es) | Derivados de quinolin-2-ona inhibidores de la farnesil proteína transferasa útiles como agentes contra el cáncer | |
| GEP20084357B (en) | Pyrimidine derivatives for the treatment of abnormal cell growth | |
| YU55603A (sh) | Derivati purina kao antagonisti purinergiskog receptora | |
| MXPA04000577A (es) | Derivados de dolastatina 10. | |
| MXPA04001240A (es) | Analogos antitumorales. | |
| TW200517109A (en) | Substituted pyridinones | |
| MXPA05010621A (es) | Pirimidinonas sustituidas. | |
| PL353337A1 (pl) | Podstawione tien-3-ylosulfonyloamino(tio)karbonylotriazolin(ti)ony | |
| HUP0204418A2 (hu) | NHE-1 inhibitor hatású N-[(helyettesített öttagú, di- vagy triaza-, kétszeresen telítetlen gyűrű)-karbonil]-guanidin-származékok és alkalmazásuk | |
| MY139612A (en) | Benzoxazine derivatives as 5-th6 modulators and uses thereof | |
| ATE233754T1 (de) | Diphenyl-piperidin derivate | |
| MY136824A (en) | Substituted benzoxazinones and uses thereof | |
| MXPA04000407A (es) | Derivados de fenilacetamido-tiazol, procedimiento para su preparacion y uso como agentes antitumorales. | |
| MY138466A (en) | Aminoalkoxyndoles as 5-ht6-receptor ligands for the treatment of cns-disorders | |
| PT1022276E (pt) | Derivados de epoxissuccinamida | |
| YU64400A (sh) | Aril fuzirana azapoliciklična jedinjenja | |
| NZ515407A (en) | 4-Phenyl-pyrimidine derivatives | |
| DE69916066D1 (de) | Neue benzoxazole mit pde-hemmender wirkung | |
| ZA200700358B (en) | Alkyl substituted indoloquinoxalines | |
| ATE214064T1 (de) | Indane-1-ol derivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammenstellungen | |
| MXPA05005340A (es) | Nuevos derivados antagonistas del receptor de la vitronectina, sus procedimientos de preparacion, su aplicacion como medicamentos y los compuestos farmaceuticos que los contienen. |